COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

7.41%

Increased from previous period

Growth of 7.41% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

6.95%

Increased from previous period

Cost growth of 6.95% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

9.37%

Increased from previous period

Growth of 9.37% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

1.83%

Increased from previous period

Margin change of 1.83% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

8.74%

Increased from previous period

Other expenses change of 8.74% versus flat Healthcare costs. Walter Schloss would verify efficiency.

Operating Expenses Growth

6.11%

Increased from previous period

Operating expenses growth near Healthcare median of 5.74%. Charlie Munger would verify industry norms.

Total Costs & Expenses Growth

6.82%

Increased from previous period

Total costs growth 1.1-1.25x Healthcare median of 5.51%. John Neff would investigate control.

Interest Expense Growth

-3.70%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

8.37%

Increased from previous period

D&A change of 8.37% versus flat Healthcare D&A. Walter Schloss would verify adequacy.

EBITDA Growth

12.58%

Increased from previous period

EBITDA change of 12.58% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

4.81%

Decreased from previous period

Margin change of 4.81% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

22.36%

Increased from previous period

Income change of 22.36% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

13.92%

Increased from previous period

Margin change of 13.92% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-108.93%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

0.80%

Decreased from previous period

Income change of 0.80% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

-6.15%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-6.26%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

5.48%

Decreased from previous period

Income change of 5.48% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

-1.80%

Decreased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

5.48%

Decreased from previous period

EPS change of 5.48% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

5.48%

Decreased from previous period

Diluted EPS change of 5.48% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

7.41%

Increased from previous period

Growth of 7.41% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

6.95%

Increased from previous period

Cost growth of 6.95% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

9.37%

Increased from previous period

Growth of 9.37% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

1.83%

Increased from previous period

Margin change of 1.83% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

8.74%

Increased from previous period

Other expenses change of 8.74% versus flat Healthcare costs. Walter Schloss would verify efficiency.

Operating Expenses Growth

6.11%

Increased from previous period

Operating expenses growth near Healthcare median of 5.74%. Charlie Munger would verify industry norms.

Total Costs & Expenses Growth

6.82%

Increased from previous period

Total costs growth 1.1-1.25x Healthcare median of 5.51%. John Neff would investigate control.

Interest Expense Growth

-3.70%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

8.37%

Increased from previous period

D&A change of 8.37% versus flat Healthcare D&A. Walter Schloss would verify adequacy.

EBITDA Growth

12.58%

Increased from previous period

EBITDA change of 12.58% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

4.81%

Decreased from previous period

Margin change of 4.81% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

22.36%

Increased from previous period

Income change of 22.36% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

13.92%

Increased from previous period

Margin change of 13.92% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-108.93%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

0.80%

Decreased from previous period

Income change of 0.80% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

-6.15%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-6.26%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

5.48%

Decreased from previous period

Income change of 5.48% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

-1.80%

Decreased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

5.48%

Decreased from previous period

EPS change of 5.48% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

5.48%

Decreased from previous period

Diluted EPS change of 5.48% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: